z-logo
open-access-imgOpen Access
A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity
Author(s) -
Marco Bardelli,
Karl Frontzek,
Luca Simonelli,
Simone Hornemann,
Mattia Pedotti,
Federica Mazzola,
Manfredi Carta,
Valeria Eckhardt,
Rocco D’Antuono,
Tommaso Virgilio,
Santiago González,
Adriano Aguzzi,
Luca Varani
Publication year - 2018
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1007335
Subject(s) - neurotoxicity , antibody , chemistry , prion protein , immunotherapy , neuroprotection , microbiology and biotechnology , biochemistry , toxicity , biology , pharmacology , immunology , immune system , medicine , disease , organic chemistry , pathology
Antibodies to the prion protein, PrP, represent a promising therapeutic approach against prion diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern. Here we describe scPOM-bi, a bispecific antibody designed to function as a molecular prion tweezer. scPOM-bi combines the complementarity-determining regions of the neurotoxic antibody POM1 and the neuroprotective POM2, which bind the globular domain (GD) and flexible tail (FT) respectively. We found that scPOM-bi confers protection to prion-infected organotypic cerebellar slices even when prion pathology is already conspicuous. Moreover, scPOM-bi prevents the formation of soluble oligomers that correlate with neurotoxic PrP species. Simultaneous targeting of both GD and FT was more effective than concomitant treatment with the individual molecules or targeting the tail alone, possibly by preventing the GD from entering a toxic-prone state. We conclude that simultaneous binding of the GD and flexible tail of PrP results in strong protection from prion neurotoxicity and may represent a promising strategy for anti-prion immunotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here